person

Michele S.

Country: Italy
Department: DIPARTIMENTO DI ONCOLOGIA MEDICA ED EMATOLOGIA - SC EMATOLOGIA

Research Overview

assignment

Clinical Trials ·

Phase II Evaluation of Tislelizumab Efficacy and Safety in De Novo Hodgkin Lymphoma Patients Ineligible for Standard Chemotherapy
An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi
A Phase 3 Randomized Study Comparing Odronextamab and Lenalidomide Versus Rituximab and Lenalidomide in Relapsed/Refractory Follicular and Marginal Zone Lymphoma

location_city

Research Sites

Centro Di Riferimento Oncologico Di Aviano

Data & Insights

medical_services

Primary Speciality

Main therapeutic area

handshake

Return Partnerships

Recurring site collaborations

202

Sites with multiple studies

Has run more than one trial at 202 of 384 partner sites.

Specializations

B-Cell Lymphomas

Specializes in investigating novel therapeutic approaches for Diffuse Large B-Cell Lymphoma (DLBCL) and B-Cell Non-Hodgkin's Lymphoma, with particular focus on innovative treatment combinations.

First-line immunochemotherapy protocols
Treatment strategies for elderly and frail patients
Combination therapies with novel agents

Indolent Lymphomas

Focuses on developing treatments for Follicular Lymphoma and Marginal Zone Lymphoma, exploring various therapeutic combinations and maintenance strategies.

Early-stage treatment protocols
Novel therapeutic combinations
Maintenance therapy approaches

Advanced Lymphomas

Investigates treatments for Hodgkin Lymphoma, Mantle Cell Lymphoma, and Chronic Lymphocytic Leukemia, with emphasis on targeted therapies.

Salvage treatment protocols
Immunotherapy applications
High-risk patient management

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.